Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications
Identifieur interne : 009A86 ( Main/Exploration ); précédent : 009A85; suivant : 009A87Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications
Auteurs : Masakazu Toi [Japon] ; Tomoe Matsumoto [Japon] ; Hiroko Bando [Japon]Source :
- Lancet Oncology [ 1470-2045 ] ; 2001.
Abstract
Since the discovery that cancer development requires the growth of new blood vessels, many investigations have revealed the key molecules in the regulation of new vessel formation. One of the most important of these molecules is vascular endothelial growth factor (VEGF) an endothelial-cell-specific mitogen and survival factor. VEGF also causes increased vascular permeability and recruits progenitor endothelial cells from the bone marrow. Clinical observations have confirmed that VEGF status is closely associated with the extent of neovascularisation and prognosis in many solid tumours. VEGF status is predictive of resistance to various treatments, including radiotherapy, chemotherapy, and endocrine therapy. Preliminary results also indicate that anti-VEGF treatment suppresses cancer progression without serious toxic effects. Various approaches for the control of cancers involving inhibition of the activity of VEGF are currently being investigated. This review considers the clinical implications of VEGF, particularly its prognostic, predictive, and therapeutic value.
Url:
DOI: 10.1016/S1470-2045(01)00556-3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 005F34
- to stream Istex, to step Curation: 005F34
- to stream Istex, to step Checkpoint: 002776
- to stream Main, to step Merge: 009F35
- to stream Main, to step Curation: 009A86
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications</title><author><name sortKey="Toi, Masakazu" sort="Toi, Masakazu" uniqKey="Toi M" first="Masakazu" last="Toi">Masakazu Toi</name></author><author><name sortKey="Matsumoto, Tomoe" sort="Matsumoto, Tomoe" uniqKey="Matsumoto T" first="Tomoe" last="Matsumoto">Tomoe Matsumoto</name></author><author><name sortKey="Bando, Hiroko" sort="Bando, Hiroko" uniqKey="Bando H" first="Hiroko" last="Bando">Hiroko Bando</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CB702190517519ECF8CA3F2DD16F5763651E87CB</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S1470-2045(01)00556-3</idno><idno type="url">https://api.istex.fr/document/CB702190517519ECF8CA3F2DD16F5763651E87CB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">005F34</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">005F34</idno><idno type="wicri:Area/Istex/Curation">005F34</idno><idno type="wicri:Area/Istex/Checkpoint">002776</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002776</idno><idno type="wicri:doubleKey">1470-2045:2001:Toi M:vascular:endothelial:growth</idno><idno type="wicri:Area/Main/Merge">009F35</idno><idno type="wicri:Area/Main/Curation">009A86</idno><idno type="wicri:Area/Main/Exploration">009A86</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications</title><author><name sortKey="Toi, Masakazu" sort="Toi, Masakazu" uniqKey="Toi M" first="Masakazu" last="Toi">Masakazu Toi</name><affiliation wicri:level="1"><country wicri:rule="url">Japon</country></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Breast Unit, Department of Surgery, Tokyo Metropolitan Komagome Hospital</wicri:regionArea><wicri:noRegion>Tokyo Metropolitan Komagome Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Matsumoto, Tomoe" sort="Matsumoto, Tomoe" uniqKey="Matsumoto T" first="Tomoe" last="Matsumoto">Tomoe Matsumoto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Bioscience Research Laboratory, Toagosei Co Ltd, Ohkubo, Tsukuba</wicri:regionArea><wicri:noRegion>Tsukuba</wicri:noRegion></affiliation></author><author><name sortKey="Bando, Hiroko" sort="Bando, Hiroko" uniqKey="Bando H" first="Hiroko" last="Bando">Hiroko Bando</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Breast Unit, Department of Surgery, Tokyo Metropolitan Komagome Hospital</wicri:regionArea><wicri:noRegion>Tokyo Metropolitan Komagome Hospital</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Lancet Oncology</title><title level="j" type="abbrev">LANONC</title><idno type="ISSN">1470-2045</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">2</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="667">667</biblScope><biblScope unit="page" to="673">673</biblScope></imprint><idno type="ISSN">1470-2045</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1470-2045</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Since the discovery that cancer development requires the growth of new blood vessels, many investigations have revealed the key molecules in the regulation of new vessel formation. One of the most important of these molecules is vascular endothelial growth factor (VEGF) an endothelial-cell-specific mitogen and survival factor. VEGF also causes increased vascular permeability and recruits progenitor endothelial cells from the bone marrow. Clinical observations have confirmed that VEGF status is closely associated with the extent of neovascularisation and prognosis in many solid tumours. VEGF status is predictive of resistance to various treatments, including radiotherapy, chemotherapy, and endocrine therapy. Preliminary results also indicate that anti-VEGF treatment suppresses cancer progression without serious toxic effects. Various approaches for the control of cancers involving inhibition of the activity of VEGF are currently being investigated. This review considers the clinical implications of VEGF, particularly its prognostic, predictive, and therapeutic value.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Toi, Masakazu" sort="Toi, Masakazu" uniqKey="Toi M" first="Masakazu" last="Toi">Masakazu Toi</name></noRegion><name sortKey="Bando, Hiroko" sort="Bando, Hiroko" uniqKey="Bando H" first="Hiroko" last="Bando">Hiroko Bando</name><name sortKey="Matsumoto, Tomoe" sort="Matsumoto, Tomoe" uniqKey="Matsumoto T" first="Tomoe" last="Matsumoto">Tomoe Matsumoto</name><name sortKey="Toi, Masakazu" sort="Toi, Masakazu" uniqKey="Toi M" first="Masakazu" last="Toi">Masakazu Toi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009A86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009A86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CB702190517519ECF8CA3F2DD16F5763651E87CB
|texte= Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications
}}
| This area was generated with Dilib version V0.6.31. |  |